IPG Investment Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

IPG Investment Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,166	Closed	-$12.5K	–	229
2023 Q4	$12.5K	Buy	+1,166	New	+$8.4K	﹤0.01%	192
2023 Q3	–	Sell	-1,185	Closed	-$8.17K	–	191
2023 Q2	$8.17K	Hold	1,185	–	–	﹤0.01%	170
2023 Q1	$18.6K	Hold	1,185	–	–	﹤0.01%	161
2022 Q4	$23.7K	Hold	1,185	–	–	0.01%	133
2022 Q3	$21.1K	Hold	1,185	–	–	0.01%	133
2022 Q2	$26K	Hold	1,185	–	–	0.01%	149
2022 Q1	$33K	Hold	1,185	–	–	0.01%	164
2021 Q4	$54K	Sell	1,185 -353	-23%	-$23.8K	0.01%	199
2021 Q3	$128K	Sell	1,538 -17	-1%	-$1.41K	0.04%	121
2021 Q2	$148K	Hold	1,555	–	–	0.04%	133
2021 Q1	$259K	Buy	+1,555	New	+$206K	0.05%	158

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IPG Investment Advisors's ONCT Position: Q1 2024 in Review

IPG Investment Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 1,166 shares — an estimated $12.5K sold.

IPG Investment Advisors first reported a position in ONCT in Q1 2021 and held it in 11 quarters. The position peaked at $259K in Q1 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

IPG Investment Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
IPG Investment Advisors sold 1,166 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.5K.
IPG Investment Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
IPG Investment Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $259K in Q1 2021.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on IPG Investment Advisors's 13F filing for Q1 2024, filed 15 May 2024.